Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYTX Kyverna Therapeutics

已收盘 07-26 16:00:00 EDT

9.84

+0.94

+10.56%

盘后9.84

+0.000.00%

16:48 EDT

最高10.07	最低8.81	成交量29.86万
今开9.02	昨收8.90	日振幅14.21%
总市值4.24亿	流通市值2.22亿	总股本4,312万
成交额285.72万	换手率1.32%	流通股本2,255万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":9.84,"timestamp":1722024000000,"preClose":8.9,"halted":0,"volume":298550,"hourTrading":{"tag":"盘后","latestPrice":9.84,"preClose":9.84,"latestTime":"16:48 EDT","volume":3627,"amount":35676.58,"timestamp":1722026934476},"delay":0,"floatShares":22545728,"shares":43115244,"eps":-11.89566,"marketStatus":"已收盘","marketStatusCode":5,"change":0.94,"latestTime":"07-26 16:00:00 EDT","open":9.02,"high":10.07,"low":8.805,"amount":2857171.8651,"amplitude":0.142135,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.89566,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":0,"listingDate":1707368400000,"adjPreClose":8.9,"postHourTrading":{"tag":"盘后","latestPrice":9.84,"preClose":9.84,"latestTime":"16:48 EDT","volume":3627,"amount":35676.58,"timestamp":1722026934476},"volumeRatio":0.948989,"impliedVol":0.309,"impliedVolPercentile":0.1895},"requestUrl":"/m/hq/s/KYTX","defaultTab":"news","newsList":[{"id":"2451378609","title":"BUZZ-Kyverna公司的硬皮症药物获得美国食品药品管理局的RMAT认定后股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2451378609","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451378609?lang=zh_cn&edition=full","pubTime":"2024-07-16 06:00","pubTimestamp":1721080829,"startTime":"0","endTime":"0","summary":"    7月15日 - ** 生物制药公司Kyverna Therapeutics   的股价在盘后交易中上涨近9%，达到10.8美元** 公司的嵌合抗原受体T细胞候选产品KYV-101获得美国FDA再生医学高级疗法 认证** KYV-101将用于治疗难治性僵人综合症患者，该综合症是一种罕见的进行性神经系统自身免疫性疾病，影响患者的行走或活动能力。** KYTX表示，RMAT指定将使其能够 \"从FDA高级官员那里获得关于高效药物开发和替代终点使用的专家指导\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","KYTX"],"gpt_icon":0},{"id":"2417265001","title":"BUZZ-Leerink 将 Kyverna 评为 \"跑赢大盘\"。","url":"https://stock-news.laohu8.com/highlight/detail?id=2417265001","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417265001?lang=zh_cn&edition=full","pubTime":"2024-03-05 00:20","pubTimestamp":1709569208,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月4日 - ** 券商Leerink 给予Kyverna Therapeutics   \"跑赢大盘\"评级，目标价为48美元。** 与该股上次收盘价相比，目标价有近73%的上涨空间 ** Leerink认为，Kyverna的CAR-T细胞疗法的早期结果表明，该疗法能够触发 \"免疫重置\"，使CAR-T疗法成为治疗自身免疫性疾病的临床前沿疗法。** CAR-T疗法涉及提取一种白细胞或T细胞，重新设计它们来攻击癌症，然后将它们输回体内。** 截至收盘，该公司股价自上月首次公开募股以来下跌了约 9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4139","KYTX"],"gpt_icon":0},{"id":"2416161907","title":"美国研究综述-CommScope 控股公司、荷兰兄弟公司、赫斯公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2416161907","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416161907?lang=zh_cn&edition=full","pubTime":"2024-03-04 15:01","pubTimestamp":1709535675,"startTime":"0","endTime":"0","summary":"    路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 CommScope Holding Company、Dutch Bros 和 Hess Corp。要点 * CommScope Holding Company   ：摩根大通将其评级从中性下调至减持  * 荷兰兄弟  ：Piper Sandler 将其评级从中性上调至增持              * Hess Corp   ：Susquehanna 将目标价从 152 美元上调至 156 美元   * Pioneer Natural Resources Co   ：苏斯克汉纳将目标价从237美元上调至246美元              * United Therapeutics Corp   ：摩根大通将目标价从294美元下调至280美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AI","CIVI","IE00B19Z3B42.SGD","GRBK","BK4020","LU1201861249.SGD","BK4585","KYTX","LU2505996681.GBP","UTHR","BK4504","LU1291159041.SGD","LU0980610538.SGD","LU2505996509.AUD","BK4206","BK4209","BK4566","MNST","LU1670627923.USD","LU1169589451.USD","SGXZ51526630.SGD","IE0002270589.USD","COMM","SWN","BLK","IE00B19Z9505.USD","LU0300736062.USD","BK4551","LU0648001328.SGD","SVRA","BK4543","BK4501","CBRL","LU1989771016.USD","GE","BROS","BK4535","NREF","HES","LU1988902786.USD","BK4587","LU0300736492.USD","LU1571399168.USD","BK4177","SGXZ81514606.USD","LU1169590202.USD","PXD","LU1435385759.SGD","LU0368265418.SGD","LU1670628061.USD"],"gpt_icon":0},{"id":"2410970990","title":"Kyverna(KYTX.US)上市首日大涨36% 美股医药IPO继续获热捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2410970990","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2410970990?lang=zh_cn&edition=full","pubTime":"2024-02-09 11:03","pubTimestamp":1707447780,"startTime":"0","endTime":"0","summary":"智通财经获悉，Kyverna Therapeutics周四纳斯达克上市，首次公开募股融资3.19亿美元。数据显示，这是自去年6月Cava Group Inc.上市筹资3.65亿美元以来，IPO融资规模超过1亿美元的最大IPO。Kyverna的主要药物是用于风湿病和神经病学自身免疫性疾病的CAR T细胞疗法。Kyverna是本周美国IPO市场繁忙的一部分，其他IPO还包括美国医疗房地产投资信托公司American Healthcare REIT，该公司筹资6.72亿美元，股价上涨近10%，以及一家墨西哥食品杂货连锁店。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-09/doc-inahmafp0689332.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-09/doc-inahmafp0689332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1515","BK1574","KYTX","159938","BK1161"],"gpt_icon":0},{"id":"2410729930","title":"BUZZ-首次公开募股规模扩大后，Kyverna Therapeutics 大涨近 60","url":"https://stock-news.laohu8.com/highlight/detail?id=2410729930","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2410729930?lang=zh_cn&edition=full","pubTime":"2024-02-09 04:09","pubTimestamp":1707422970,"startTime":"0","endTime":"0","summary":"    2月8日 - ** Kyverna Therapeutics   周四首次公开募股超预期，股价大涨** KYTX 开盘价为 34.25 美元，最高交易价为 35.06 美元，比 22 美元的首次公开募股价格高出 59.4** 由吉利德科学公司  支持的公司出售了1450万股股票，价格比已经上调的20-21美元区间高出1美元，融资3.19亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4585","LU0234570918.USD","BK4588","LU0109394709.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU1571399168.USD","BK4578","LU1585245621.USD","LU0889565916.HKD","IE00BSNM7G36.USD","BK4532","LU0289739699.SGD","GILD","LU0320765992.SGD","LU1066051498.USD","LU2087621335.USD","LU1839511570.USD","KYTX","BK4568","LU1066053197.SGD","BK4566","LU0058720904.USD","BK4139","LU2468319806.SGD","IE00BKVL7J92.USD","BK4550","BK4583"],"gpt_icon":0},{"id":"2410723899","title":"吉利德支持的 Kyverna Therapeutics 首次亮相即估值 14 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2410723899","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2410723899?lang=zh_cn&edition=full","pubTime":"2024-02-09 02:41","pubTimestamp":1707417708,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透2月8日 - 周四，Kyverna Therapeutics   股价首次上市就大涨55.7%，使这家由吉利德科学公司  支持的生物制药公司市值达到14亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2409509137","title":"今年美股药企第二大IPO来了！Kyverna(KYTX.US)今晚上市 筹资3.19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409509137","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409509137?lang=zh_cn&edition=full","pubTime":"2024-02-08 14:36","pubTimestamp":1707374166,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，随着药物开发商继续受到新投资者的热烈欢迎，Kyverna Therapeutics Inc.在美国首次公开募股中筹集了3.19亿美元，发行价高于此前的定价区间。汇编数据显示，此次发行是今年药物开发公司中规模第二大IPO，仅次于专注于癌症的CG Oncology Inc.两周前筹集了4.37亿美元。据了解，Kyverna的主要药物是CAR T细胞疗法，用于治疗风湿病和神经病学中的自身免疫性疾病。由Moderna支持的Metagenomi Inc.定于周四定价，生物技术行业今年的IPO募资或将超过10亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1070896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KYTX"],"gpt_icon":0},{"id":"2409753609","title":"Kyverna Therapeutics 将在规模更大的首次公开募股中融资 3.19 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409753609","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409753609?lang=zh_cn&edition=full","pubTime":"2024-02-08 12:03","pubTimestamp":1707365033,"startTime":"0","endTime":"0","summary":"    路透2月8日 - 吉利德支持的Kyverna Therapeutics公司周三表示，该公司将以8.981亿美元的估值在规模更大的美国 首次公开募股中融资3.19亿美元。该公司 表示，计划以每股22美元的价格出售1450万股股票，高于此前每股20-21美元的价格区间。Kyverna由吉利德科学公司  和贝恩资本生命科学机会公司支持 ，是一家处于临床阶段的细胞疗法公司，旨在为自身免疫性疾病患者带来改变疾病的治疗效果。公司股票 将于 2 月 8 日开始在纳斯达克交易，股票代码为 \"KYTX\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4568","LU1571399168.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU1839511570.USD","LU1585245621.USD","LU2468319806.SGD","BK4583","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU1066051498.USD","BK4566","KYTX","BK4585","LU0889565916.HKD","BK4550","BK4578","LU1066053197.SGD","GILD","LU0058720904.USD","BK4139","LU2087621335.USD","LU0234570918.USD","LU0320765992.SGD","BK4532","BK4588","LU1430594728.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kyvernatx.com","stockEarnings":[{"period":"1week","weight":-0.1508},{"period":"1month","weight":0.1499},{"period":"3month","weight":-0.4247},{"period":"6month","weight":-0.5955},{"period":"ytd","weight":-0.5955}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kyverna Therapeutics, Inc.于2018年6月以BAIT Therapeutics, Inc.的名义在特拉华州注册成立，并于2019年10月更名为Kyverna Therapeutics, Inc.。该公司是一家以患者为中心的临床阶段生物制药公司，专注于为患有自身免疫性疾病的患者开发细胞疗法。他们的目标是通过以患者为中心的方法、广泛的平台、对治疗免疫疾病的见解以及从细胞疗法在其他医学领域的成功应用中获得的经验，为患有自身免疫性疾病的患者带来改善疾病的治疗益处。","exchange":"NASDAQ","name":"Kyverna Therapeutics","nameEN":"Kyverna Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kyverna Therapeutics,KYTX,Kyverna Therapeutics股票,Kyverna Therapeutics股票老虎,Kyverna Therapeutics股票老虎国际,Kyverna Therapeutics行情,Kyverna Therapeutics股票行情,Kyverna Therapeutics股价,Kyverna Therapeutics股市,Kyverna Therapeutics股票价格,Kyverna Therapeutics股票交易,Kyverna Therapeutics股票购买,Kyverna Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}